Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma

• Published in: International journal of urology 2015-02, Vol.22 (2), p.153-157
• Main Authors: Park, Yong Hyun, Jung, Jin-Woo, Lee, Byung Ki, Lee, Sangchul, Jeong, Seong Jin, Byun, Seok-Soo, Lee, Sang Eun
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Carcinoma, Renal Cell - diagnosis; Carcinoma, Renal Cell - secondary; Carcinoma, Renal Cell - therapy; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; immediate postoperative targeted therapy; Kidney Neoplasms - pathology; Kidney Neoplasms - therapy; Male; metastasectomy; metastatic renal cell carcinoma; Middle Aged; Neoplasm Metastasis; Nephrectomy; Postoperative Care - methods; Republic of Korea - epidemiology; Retrospective Studies; Survival Rate - trends
• ISSN: 0919-8172; 1442-2042
• DOI: 10.1111/iju.12662

Objectives To evaluate the efficacy of targeted therapy after complete resection of metastatic lesions in patients with metastatic renal cell carcinoma. Methods We retrospectively reviewed the medical records of 53 patients with metastatic renal cell carcinoma who underwent complete surgical resection of metastatic lesions between January 2006 and December 2012. Immediate postoperative targeted therapy was given to a subgroup of patients. Progression‐free survival and cancer‐specific survival were assessed. Results All patients underwent curative surgery for a primary tumor. A total of 13 patients (24.5%) had metastatic disease at initial diagnosis, and 49 (92.5%) had single‐organ involvement at the time of first metastasis. None of the patients met the poor‐risk criteria. Of the 19 patients who received immediate postoperative targeted therapy, five (26.3%) experienced relapse. Of the 34 patients who did not receive immediate postoperative targeted therapy, 27 (79.4%) experienced disease recurrence. Targeted therapy was restarted in 30 patients (93.8%) after relapse with excellent disease control rates (complete response: 3.3%, partial response: 36.7%, stable disease: 46.7%). Immediate postoperative targeted therapy was associated with better median progression‐free survival (not reached vs 20.0 months; P = 0.017), but not better cancer‐specific survival. Conclusions Postoperative targeted therapy after complete metastasectomy seems to be associated with better progression‐free survival in patients with metastatic renal cell carcinoma, but not with cancer‐specific survival.